Assess whether the primary endpoint will survive FDA scrutiny (f3ee63)

SITUATION Disproportionate reporting signal workbook arrived with an AdCom briefing document that overstates subgroup findings for CMC change-control owner. That is a Pharma & Life Sciences Clinical and Evidence Strategy decision on the primary endpoint will in a safety team sitting on a new disproportionate signal.

DECISION CMC change-control owner in a safety team sitting on a new disproportionate signal must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using disproportionate reporting signal workbook after an AdCom briefing document that overstates subgroup findings.

HYPOTHESES TO TEST 1. CMC change-control owner can defend Proceed under protocol from disproportionate reporting signal workbook after an AdCom briefing document that overstates subgroup findings in a Pharma & Life Sciences challenge. 2. CMC change-control owner cannot defend Proceed under protocol from disproportionate reporting signal workbook; Pause the pathway is what the extract actually supports after an AdCom briefing document that overstates subgroup findings. 3. An AdCom briefing document that overstates subgroup findings never reached the population in disproportionate reporting signal workbook — reopen intake, do not close the primary endpoint will. 4. Two facts in disproportionate reporting signal workbook after an AdCom briefing document that overstates subgroup findings conflict for CMC change-control owner; hold this Clinical and Evidence Strategy file.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in disproportionate reporting signal workbook after an AdCom briefing document that overstates subgroup findings. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on the primary endpoint will. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read disproportionate reporting signal workbook against an AdCom briefing document that overstates subgroup findings and write the one fact that would move the primary endpoint will for CMC change-control owner.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (disproportionate reporting signal workbook after an AdCom briefing document that overstates subgroup findings). The follow-on Clinical and Evidence Strategy action is what CMC change-control owner does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on the primary endpoint will, then the evidence in disproportionate reporting signal workbook, then the action for CMC change-control owner - Hypothesis scorecard against disproportionate reporting signal workbook: supported / rejected / untestable - Named option among Proceed under protocol, Pause the pathway, Escalate safety review and the fact that kills the others - Owner and next date for CMC change-control owner in a safety team sitting on a new disproportionate signal